Special Issue "Nanotechnology and Cancer Therapeutics"
A special issue of Cancers (ISSN 2072-6694).
Deadline for manuscript submissions: closed (30 November 2010)
Dr. Shaker A. Mousa
Pharmaceutical Research Institute at Albany College of Pharmacy and Health Sciences, 1 Discovery Drive (Room 238), Rensselaer, New York 12144, USA
Phone: +1 518 694 7397
Fax: +1 518-694 7567
Interests: Drug discovery and drug development utilizing key enabling technologies including nanotechnology; biotechnology, stem cell, and novel pharmacotherapy; cell adhesion molecules and extracellular matrix; treatment and prevention of ischemic and coronary artery diseases; angiogenesis modulation; vascular and tissue remodeling; novel anti-platelet, anti-thrombotic and early detection and treatment of diseases with unmet medical need ranging from oncology, ophthalmology, cardiovascular, and vascular disorders
I would like to take this opportunity in inviting review articles having key innovations that would help accelerate progress in the field of Nanotechnology in early cancer detection and treatment. It is becoming clear to all of us that the application of nanotechnology and biotechnology utilizing nanoparticles for combined targeting and delivery of diagnostic and therapeutic agents has tremendous potential for early detection and treatment of various disorders. Nanoparticles may be constructed from a wide range of organic and inorganic materials such as emulsions, micelles, liposomes, dendrimers, quantum dots, and other polymeric materials. These materials are being used to encapsulate or covalently bind to the surface of the nanoparticles site directed moiety (s). Several multifunctional nanoparticles are being evaluated in early detection and therapeutics.
The next generation of nanoparticles-based research is directed at the consolidation of functions into strategically engineered multifunctional devices, which may ultimately facilitate the realization of individual therapy. These nanoparticles may be capable of (a) improving delivery of hydrophobic compounds (water insoluble); (b) improving stability of unstable peptides or easily inactivated compounds such as polyphenols and others; (c) identifying malignant cells via molecular detection; (c) visualizing their location in the body by providing enhanced contrast in medical imaging techniques; (d) targeting and killing diseased cells with minimal side effects through selective cell or tissue targeting; (e) polyvalent antidote for reversal of intoxication or toxins; and (f) delivering multiple drug targets for combination therapy.
One of the best known examples for reformulated, nanoparticles-based drug delivery is Doxil. Doxil, approved in the U.S. in 1995, is the poly (ethylene glycol)-coated, liposome-encapsulated form of doxorubicin in cancer chemotherapy. A more recent commercial product Abraxane, consists of an albumin-based reformulation of paclitaxel, which was approved in the U.S. in 2005. Other examples are in preclinical and early clinical investigations.
Dr. Shaker A. Mousa
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. Papers will be published continuously (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are refereed through a peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed Open Access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 500 CHF (Swiss Francs). English correction and/or formatting fees of 250 CHF (Swiss Francs) will be charged in certain cases for those articles accepted for publication that require extensive additional formatting and/or English corrections.
- early detection using in vivo imaging modalities
- site directed delivery of chemotherapy into different tumor types using specific directed targets metal nanoparticles such as gold nanoparticles in the detection and treatment of breast cancer, and other types of cancer
- use of nanotechnology with nutraceuticals for chemoprevention
Cancers 2010, 2(4), 1884-1894; doi:10.3390/cancers2041884
Received: 28 October 2010; in revised form: 2 November 2010 / Accepted: 9 November 2010 / Published: 17 November 2010| Download PDF Full-text (228 KB) | Download XML Full-text
Review: A Comparative Study of Two Folate-Conjugated Gold Nanoparticles for Cancer Nanotechnology Applications
Cancers 2010, 2(4), 1911-1928; doi:10.3390/cancers2041911
Received: 29 October 2010; in revised form: 10 November 2010 / Accepted: 11 November 2010 / Published: 18 November 2010| Download PDF Full-text (815 KB) | Download XML Full-text
Cancers 2011, 3(1), 17-42; doi:10.3390/cancers3010017
Received: 12 November 2010; in revised form: 10 December 2010 / Accepted: 22 December 2010 / Published: 23 December 2010| Download PDF Full-text (692 KB) | Download XML Full-text
Article: Doxorubicin-Loaded PEG-PCL-PEG Micelle Using Xenograft Model of Nude Mice: Effect of Multiple Administration of Micelle on the Suppression of Human Breast Cancer
Cancers 2011, 3(1), 61-78; doi:10.3390/cancers3010061
Received: 11 November 2010; in revised form: 20 December 2010 / Accepted: 27 December 2010 / Published: 28 December 2010| Download PDF Full-text (1187 KB) | Download XML Full-text
Article: Anti-Neuroblastoma Activity of Gold Nanorods Bound with GD2 Monoclonal Antibody under Near-Infrared Laser Irradiation
Cancers 2011, 3(1), 227-240; doi:10.3390/cancers3010227
Received: 7 December 2010; in revised form: 26 December 2010 / Accepted: 4 January 2011 / Published: 6 January 2011| Download PDF Full-text (539 KB) | Download XML Full-text
Review: Progress in Nanotechnology Based Approaches to Enhance the Potential of Chemopreventive Agents
Cancers 2011, 3(1), 428-445; doi:10.3390/cancers3010428
Received: 14 December 2010; in revised form: 4 January 2011 / Accepted: 12 January 2011 / Published: 21 January 2011| Download PDF Full-text (291 KB) | Download XML Full-text
Cancers 2011, 3(1), 802-840; doi:10.3390/cancers3010802
Received: 19 January 2011; in revised form: 12 February 2011 / Accepted: 17 February 2011 / Published: 23 February 2011| Download PDF Full-text (1984 KB) | Download XML Full-text
Cancers 2011, 3(1), 1081-1110; doi:10.3390/cancers3011081
Received: 17 December 2010; in revised form: 19 January 2011 / Accepted: 21 January 2011 / Published: 4 March 2011| Download PDF Full-text (1890 KB) | Download XML Full-text
Cancers 2011, 3(3), 3279-3330; doi:10.3390/cancers3033279
Received: 16 June 2011; in revised form: 7 July 2011 / Accepted: 8 August 2011 / Published: 12 August 2011| Download PDF Full-text (889 KB) | Download XML Full-text
Review: High Resolution Fluorescence Imaging of Cancers Using Lanthanide Ion-Doped Upconverting Nanocrystals
Cancers 2012, 4(4), 1067-1105; doi:10.3390/cancers4041067
Received: 13 August 2012; in revised form: 20 September 2012 / Accepted: 15 October 2012 / Published: 22 October 2012| Download PDF Full-text (2057 KB) | Download XML Full-text
Last update: 25 September 2012